PEG MGF 5 mg PEG MGF 5 mg
Peptide Hubs

PEG MGF 5 mg

Product Details Peptide Hubs
Active Substance PEG-MGF PEGylated Mechano Growth Factor
Strength 5 mg/vial
Vial Size 2 mL vial
Form Lyophilized powder For reconstitution
Research Class IGF-1-related peptide PEGylated MGF E-peptide
Peptide Core 24 amino acids IGF-1Ec E-domain
Human Half-Life Not established
Modification PEGylated Polyethylene glycol conjugate
Latest laboratory result 5.75 mg/vial January 12, 2026 · 115.00% of 5 mg label claim · Batch #GAPEG12 View
$39.00 $65.00
Shipping Location :
International
U.S. Domestic
You will save $26.00

PEG MGF 5 mg by Peptide Hubs: Advanced Pegylated Muscle Growth Factor for Research

Peptide Hubs introduces its premium research compound, PEG MGF 5 mg, a cutting-edge, pegylated form of Mechano Growth Factor (MGF) designed for investigative studies into localized muscle repair, cellular hyperplasia, and post-exercise recovery. As a specialized splice variant of Insulin-like Growth Factor-1 (IGF-1), native MGF is rapidly produced in muscle tissue following mechanical stress or damage, acting as a critical local repair signal. However, its extremely short half-life limits its research applicability. Our PEG MGF (pegylated MGF) solves this by conjugating a polyethylene glycol (PEG) molecule to the peptide, dramatically extending its stability and active half-life in the systemic circulation from minutes to approximately 20-30 hours. This innovation allows researchers to study sustained, localized anabolic and reparative effects. Manufactured under stringent controls in a USA laboratory, each 2 mL vial contains 5 mg of highly pure, pegylated lyophilized powder, providing a reliable and potent tool for advanced sports science and muscle physiology research.

Mechanism of Action and Research Effects

PEG MGF's primary research effects stem from its unique mechanism as a localized growth factor. Upon intramuscular injection, it binds to IGF-1 receptors on satellite cells (muscle stem cells), activating key pathways for muscle protein synthesis and cellular proliferation. Unlike systemic anabolic agents, its pegylation allows it to exert more localized effects, making it a subject of interest for studying "spot enhancement" and targeted muscle repair. Key observed effects in research models include: Promotion of Muscle Hyperplasia: It stimulates the activation and differentiation of satellite cells, leading to an increase in the actual number of muscle fibers (hyperplasia), complementing hypertrophy (fiber growth). Enhanced Muscle Repair & Recovery: It accelerates the repair of micro-tears caused by intense mechanical training, reducing downtime and potentially mitigating delayed onset muscle soreness (DOMS). Localized Nutrient Uptake: It increases glucose and amino acid uptake specifically in the injected muscle, enhancing nutrient partitioning for repair and growth. These properties make it a compelling compound for research into rehabilitation from muscle injury and optimizing training adaptations. The foundational science behind growth factor signaling in muscle can be explored in depth through resources like the NIH PubMed Central (PMC) database.

Technical Details

Peptide Type
PEGylated Synthetic Peptide
MGF Core Sequence
YQPPSTNKNTKSQRRKGSTFEERK
Peptide Core Length
24 Amino-Acid Residues
Structural Origin
IGF-1Ec C-Terminal E-Domain
Modification
Polyethylene Glycol (PEG) Conjugation
PEG Specification
Not Specified for This Product
Parent Gene
IGF1
Research Status
Experimental / Preclinical

Dosage & Usage Guidelines

PEG MGF is administered via intramuscular (IM) injection, preferably into the muscle group targeted for study, such as the quadriceps, pectorals, or deltoids. The pegylated form allows for less frequent dosing compared to the native version. A common research dosage ranges from **100 mcg to 300 mcg per injection site**, with protocols often administering doses 2-3 times per week (e.g., Monday, Wednesday, Friday). The total weekly research dose typically remains between 600 mcg to 1000 mcg (0.6 to 1.0 mg). To reconstitute the 5 mg vial, researchers commonly use 2 mL of sterile bacteriostatic water, yielding a concentration of 2.5 mg/mL (or 2500 mcg/mL). At this concentration, 0.1 mL (10 units on an insulin syringe) contains 250 mcg. It is crucial to rotate injection sites to allow for localized recovery and to adhere to strict aseptic laboratory techniques. Dosing should be based on the specific research objectives and model characteristics.

Recommended Research Cycle and Synergistic Stacks

Research cycles for studying PEG MGF's effects on muscle adaptation are typically shorter than systemic anabolic cycles, often lasting **4 to 8 weeks**. Longer cycles may be designed for injury rehabilitation studies. Due to its localized and non-hormonal nature, it can be effectively combined with other peptides and compounds to create comprehensive research stacks. For systemic anabolic support and IGF-1 receptor saturation, researchers often pair it with IGF-1 LR3, which has a longer systemic half-life. To support the foundational recovery of connective tissues and tendons stressed during heavy training, combining with TB-500 / BPC 157 blend is highly logical. For enhancing natural growth hormone pulses to create a more anabolic environment, adding a secretagogue like GHRP-6 10 mg can be studied. Furthermore, to support cellular energy and mitochondrial function during intense repair processes, research into stacking with NAD+ 100 mg is an emerging area of interest. Post-cycle, researchers may investigate the role of peptides like Epitalon 50 mg in supporting cellular rejuvenation and telomere maintenance after periods of intense cellular proliferation.

Possible Side Effects and Research Considerations

In a controlled research setting, PEG MGF is generally well-tolerated due to its localized, non-hormonal action. The most commonly noted potential side effects are localized to the injection site and may include transient soreness, redness, or swelling, which usually subside within 24-48 hours. Proper injection technique and site rotation minimize this. There is a hypothetical risk of disproportionate or asymmetrical muscle growth if injection sites are not rotated evenly, which is a key variable for researchers to control. Unlike androgenic compounds, PEG MGF does not cause androgenic side effects such as acne, hair loss, or prostate enlargement. It does not aromatize into estrogen, so water retention, gynecomastia, and high blood pressure from estrogenic activity are not concerns. There is no reported hepatotoxicity or significant impact on the HPTA (hypothalamic-pituitary-testicular axis). Researchers should monitor for any signs of localized infection or unusual tissue reaction. All research must be conducted responsibly, with the understanding that this compound is for laboratory investigation only.

PEGylation: The Technology Behind Extended Activity

The "PEG" in PEG MGF is not merely a label; it represents a critical pharmaceutical technology. PEGylation involves attaching strands of polyethylene glycol to the peptide molecule. This process increases the peptide's molecular size, which reduces its rate of renal clearance and protects it from enzymatic degradation (proteolysis). The result is a dramatically extended circulatory half-life, allowing the MGF to remain bioactive long enough to exert sustained effects on target tissues. This also allows for less frequent dosing in research protocols. Peptide Hubs utilizes a precise, controlled PEGylation process to ensure a consistent and active conjugate in every vial, giving researchers a reliable tool to study the prolonged effects of this potent growth factor.

Quality Assurance and Research Integrity

Every batch of Peptide Hubs PEG MGF 5 mg is synthesized in a state-of-the-art, USA-based facility adhering to strict quality control protocols. The final lyophilized product undergoes rigorous analytical testing, including High-Performance Liquid Chromatography (HPLC) to verify purity (>99%), Mass Spectrometry (MS) for sequence and mass confirmation, and endotoxin testing. This commitment to quality ensures researchers receive a precisely dosed, contaminant-free compound, allowing for reproducible and valid experimental outcomes. We stand behind the integrity of our products to support the advancement of legitimate scientific inquiry.

Batch-Tested & Verified Lab Results

PEG MGF 5 mg analytical report dated January 12, 2026, showing 5.75 mg
January 12, 2026 Latest Report
5.75 mg
Label Strength 5 mg
Assay vs Label 115.00%
View Report

Shipping & Product Authenticity

USA Domestic
4–5 business days
International
13–15 business days
Order Processing
24–48 business hours
Tracking
Tracking number provided
Direct Supply & Discreet Delivery

This product is supplied through the official Peptide Hubs distribution chain and shipped in original manufacturer packaging. The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details.

What to Expect

  • βœ” Orders are processed after payment confirmation
  • βœ” USA Domestic shipping is typically faster when local stock is selected
  • βœ” International orders include tracking, though update frequency may vary by destination
  • βœ” Multiple warehouses may result in separate shipments when applicable
Authenticity support: official Peptide Hubs presentation, batch-linked lab proof, and original packaging help reinforce product legitimacy and buyer confidence.
Verified Supply

For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.

Storage

Store the lyophilized powder at controlled room temperature (15–25°C) in a dry, dark place, away from direct light and moisture. The unopened vial should be kept in its original packaging to maintain stability.

After reconstitution, store the solution at 2–8°C and use within 14 days. Do not freeze. Discard any unused portion after the recommended storage period. Before use, inspect the solution and avoid use if it appears cloudy, discolored, or contains particulate matter, or if the vial or seal is compromised.

Keep out of reach of children. Follow proper handling and sterile injection practices during research use.

Proper storage conditions help maintain product stability and consistent performance across the product's shelf life.

Frequently Asked Questions

What is the key difference between PEG MGF and regular MGF or IGF-1 LR3?

The key difference is stability and action. Native MGF has a half-life of only a few minutes, making practical research difficult. PEG MGF's pegylation extends its half-life to ~20-30 hours. Unlike IGF-1 LR3, which is designed for systemic, whole-body effects, PEG MGF is primarily researched for its localized, site-specific effects when injected intramuscularly, making it ideal for studies on targeted muscle repair and hyperplasia.

Should PEG MGF be injected on training days or rest days?

Research protocols vary, but a common method is to administer PEG MGF on rest days or post-workout, not immediately pre-workout. The rationale is that its primary research role is in repair and recovery. Injecting it when the muscle is in a reparative state (post-damage) may align better with its physiological function of activating satellite cells and initiating the muscle repair cascade.

Can PEG MGF cause kidney strain or other organ stress?

There is no direct clinical evidence that PEG MGF causes kidney strain. As a peptide, it is metabolized into amino acids. The PEG molecule is biologically inert and is cleared over time. However, responsible research always includes monitoring of general health markers. It is not hepatotoxic. For research into organ support alongside growth protocols, peptides like Cardiogen 20 mg for cardiovascular health or Livagen 20 mg for liver support may be of interest for separate investigative streams.

Is post-cycle therapy (PCT) needed after a PEG MGF research cycle?

No, traditional PCT is not required. PEG MGF is a non-hormonal, non-steroidal peptide. It does not suppress the hypothalamic-pituitary-testicular axis (HPTA) like androgenic steroids, so there is no need for SERMs (like Clomid or Nolvadex) to restore natural hormone production. Research subjects' endogenous testosterone and estrogen levels should remain unaffected.

How does Peptide Hubs ensure the purity and correct pegylation of its PEG MGF?

We employ a multi-step verification process. After synthesis, the product is analyzed via Mass Spectrometry (MS) to confirm the accurate mass of the pegylated conjugate, proving successful PEGylation. High-Performance Liquid Chromatography (HPLC) is used to quantify purity and ensure the absence of free (unpegylated) MGF or other impurities. Batch-specific Certificates of Analysis documenting these results are available, ensuring researchers receive a precisely engineered product.

No reviews found

Please log in to write PEG MGF 5 mg review.

Related Offers
Lab Tested
Domestic & International
-40% OFF
Ipamorelin 5 mg
Peptide Hubs
Product Details Peptide Hubs
Active Substance Ipamorelin
Strength 5 mg/vial
Vial Size 2 mL vial
Form Lyophilized powder For reconstitution
Research Class GH secretagogue
Peptide Length 5 amino acids Pentapeptide
Terminal Half-Life ~2 hours
Primary Target GHS-R Ghrelin receptor pathway
Latest laboratory result 4.65 mg/vial January 12, 2026 · 93.00% of 5 mg label claim · Batch #GAIPA12 View
$26.40 $44.00
You will save $17.60
Lab Tested
Domestic & International
NEW
-40% OFF
MOTS-c 10 mg
Peptide Hubs
Product Details Peptide Hubs
Active Substance MOTS-c Mitochondrial-derived peptide
Strength 10 mg/vial
Vial Size 2 mL vial
Form Lyophilized powder For reconstitution
Research Class Mitochondrial peptide
Peptide Length 16 amino acids
Human Half-Life Not established
Research Pathway AMPK signaling Metabolic research
Latest laboratory result 11.50 mg/vial January 12, 2026 · 115.00% of 10 mg label claim · Batch #GAMOT12 View
$40.80 $68.00
You will save $27.20
Shipped International
-40% OFF
IGF-1 LR3 1 mg
Peptide Hubs
Product Details Peptide Hubs
Active Substance IGF-1 LR3 Long R3 IGF-1
Strength 1 mg/vial
Vial Size 2 mL vial
Form Lyophilized powder For reconstitution
Research Class IGF-1 analogue
Peptide Length 83 amino acids
Human Half-Life Not established
Primary Target IGF-1 receptor IGF-1R signaling
$45.00 $75.00
You will save $30.00
Lab Tested
Domestic & International
NEW
-40% OFF
GHK-Cu 50 mg
Peptide Hubs
Product Details Peptide Hubs
Active Substance GHK-Cu Copper tripeptide-1
Strength 50 mg/vial
Vial Size 2 mL vial
Form Lyophilized powder For reconstitution
Research Class Copper-binding peptide
Peptide Sequence Gly-His-Lys Tripeptide
Copper Complex Cu2+
Human Half-Life Not established
Latest laboratory result 61.51 mg/vial January 12, 2026 · 123.02% of 50 mg label claim · Batch #GAGHK12 View
$27.00 $45.00
You will save $18.00

Add to Cart - Product(s)

Close Button
Empty

Total Cost: